|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 905 16th ST NW |
Address2 | Suite 400 |
City | Washington |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Schaumburg |
State | IL |
Zip Code | 60173-4973 |
Country | USA |
|
5. Senate ID# 3388-12
|
||||||||
|
6. House ID# 315460000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Manuel Bonilla |
Date | 1/19/2023 5:23:09 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare sequester, PAYGO
S. 1512, CONNECT for Health Act of 2021: Telehealth
H.R. 2903, CONNECT for Health Act of 2021: Telehealth
H.R. 5932, The Inpatient Opioid Safety Act: patient safety
Medicare for All/Public Option
Rural Anesthesiology: Rural Pass Through
Out of Network/Out of Network Payment
Network Adequacy
Historical Medicare payment undervaluation for anesthesiology services (33% problem)
Anesthesia Conversion Factor
Perioperative Surgical Home Model
Bundled payments
CMS Interpretive Guidelines: Hospital Conditions of Participation Related to Anesthesia Services
Medicare Physician Fee Schedule Rule
CMS Value-Based purchasing
CMS Medicare Data Final Rule
Conditions of Participation - Anesthesia services, opt-outs, supervision
Physician Quality Reporting System, PPACA, Sec. 3007 Quality Modifier implementation
Graduate Medical Education
Value-based modifier - PPACA
Debt ceiling - Medicare sequestration
QCDR - Qualified Clinical Data Registry
CMS Meaningful Use Stage 3
Evaluation and Monitoring codes & cuts
Certified Anesthesiologist Assistants
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Government Accountability Office (GAO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Manuel |
Bonilla |
|
|
|
Nora |
Matus |
|
|
|
Matthew |
Popovich |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Practice Support/Grants to Practice
Foreign physician immigration status
Medical liability
H.R. 7259, Medical Controlled Substances Transportation Act of 2022: to enable physicians to more easily transport controlled substances safely and legally across state lines
H.R. 133, the Consolidated Appropriations Act, 2021: No Surprises Act, surprise medical billing
H.R. 2630, Extending Temporary Emergency Scheduling of Fentanyl Analogues Act: Opioids
H.R. 3502, Protecting People From Surprise Medical Bills Act: Surprise Medical Bills
S. 445, Mainstreaming Addiction Treatment Act of 2021: Opioids
H.R. 4387, Maternal Health Quality Improvement Act of 2021: Maternal health
H.R. 1565, Saving Lives, Saving Costs
S. 1475, Saving Lives, Saving Costs
S. 610, Dr. Lorna Breen Health Care Provider Protection Act: Physician wellness
H.R. 1667, Dr. Lorna Breen Health Care Provider Protection Act: Physician wellness
S. 987, CARA 3.0 Act of 2021: Opioids
H.R. 3259, NOPAIN Act: Opioids
S. 586, NOPAIN Act: Opioids
S. 1292, Non-Opioid Directive Act: Opioids
H.R. 7961, SAVE Act: To protect hospital personnel from violence, and for other purposes.
FY 2021 LHHS Appropriations: Fiscal Year 2021 Appropriations for Subcommittee on Labor, Health and Human Services
Pre-authorization; prior authorization
Affordable Care Act reform efforts
Medical Controlled Substances Transportation
42 CFR Part 2, Confidentiality of Substance Use Disorder Patient Records: appropriate access to patient information essential for providing whole-person care
Resident Education Deferred Interest Act (REDI Act): Student loan relief
Student Loan Forgiveness for Frontline Health Workers Act: Student loan relief
H.R. 842, Protecting the Right to Organize Act of 2021: PRO Act, labor protections
21st Century Cures Initiative
H.R. 4369, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act: Drug shortages
DEA Scheduling Propofol
Comparative Effectiveness Research - PCORI
HITECH Implementation, Electronic Health Records, Final and Proposed Rules, HIT Meaningful Use
HHS/OIG Anesthesia Practice Arrangements, Company Model
FDA Safe Use Initiative
Pain Management
FTC Letters to States re: Interventional Pain Medicine & Advanced Practice Nurses & Competition in Healthcare
Anesthesia Research Funding (Pediatric and others)
Scope of Practice
FDA Operating Room Fires
Naloxone
FDA Opioids
Ketamine use by law enforcement
Prescription Drug Abuse
FDA Network of Experts
NIH Interagency Pain Research Coordinating Committee
USP - US Pharmacopeia
National Pain Strategy
Nondiscrimination
Compounding
FDA Nominations to Advisory Committees (Anesthesia Drugs, Anesthesia Devices, Compounding)
Agency for Healthcare Research and Quality (AHRQ) funding
Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS)
Brain health
Certified Anesthesiologist Assistants
Blood management
Funding for physician practices impacted by the cancellation of elective surgeries, unique role of anesthesiologists in responding to COVID-19 pandemic, medical liability, scope of Practice (waiver of federal supervision requirement under the Emergency Declaration), insurance moratorium; COVID Update Memorandum 4/21/20
Long COVID research
Anesthesia workforce shortages
CDC Opioid Prescribing Guideline
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Justice - Dept of (DOJ), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Management & Budget (OMB), Executive Office of the President (EOP), Defense - Dept of (DOD), Occupational Safety & Health Administration (OSHA), Federal Trade Commission (FTC), Veterans Affairs - Dept of (VA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), White House Office, Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Manuel |
Bonilla |
|
|
|
Nora |
Matus |
|
|
|
Matthew |
Popovich |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Veterans Affairs Advance Practice Registered Nurses
Milcon VA Annual Appropriations
VA Physician/Provider Hiring
VA Stone Memorandum, April 21, 2020: physician supervision
Federal Supremacy Initiative (National Standards of Practice): reduction in patient safety standard
H.R.7048, Protect Lifesaving Anesthesia Care for Veterans Act of 2022: anesthesia care
17. House(s) of Congress and Federal agencies Check if None
Veterans Affairs - Dept of (VA), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Manuel |
Bonilla |
|
|
|
Nora |
Matus |
|
|
|
Matthew |
Popovich |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |